key: cord-0846084-7bpwnoz5
authors: Papasavas, Pavlos; Olugbile, Sope; Wu, Ulysses; Robinson, Kenneth; Roberts, Amity L.; O’Sullivan, David M.; McLaughlin, Tara; Mather, Jeffrey F.; Steinberg, Adam C.; Orlando, Rocco; Kumar, Ajay
title: Seroprevalence of SARS-CoV-2 antibodies, associated epidemiological factors and antibody kinetics among healthcare workers in Connecticut
date: 2021-04-27
journal: J Hosp Infect
DOI: 10.1016/j.jhin.2021.04.021
sha: 87584ee6b1af16c420889669fc6a3ee9cf22f63d
doc_id: 846084
cord_uid: 7bpwnoz5

BACKGROUND: Healthcare workers (HCWs) are at the front line of the ongoing coronavirus pandemic. Comprehensively evaluating SARS-CoV-2 seroprevalence among HCWs in a large healthcare system could help identify the impact that epidemiological factors and presence of symptoms have on immune response to the infection over time. AIM: To determine the seroprevalence of SARS-CoV-2 specific antibodies among healthcare workers (HCWs), to identify associated epidemiological factors and to study antibody kinetics. METHODS: We completed a longitudinal evaluation of the seroprevalence and epidemiology of SARS-CoV-2 specific antibodies in approximately 30,000 HCWs in the largest healthcare system in the State of Connecticut. FINDINGS: The baseline prevalence of SARS-CoV-2 antibody among 6,863 HCWs was 6.3% (95% CI: 5.7%-6.9%) and was highest among patient care support (16.7%), medical assistants (9.1%), and nurses (8.2%) and lower for physicians (3.8%) and advanced practice providers (4.5%). Seroprevalence was significantly higher among African Americans (OR 3.26 compared to Caucasians, 95% CI 1.77-5.99), in participants with at least one COVID symptom (OR 3.00, 95% CI 1.92-4.68), and in those reporting prior quarantine (OR 3.83, 95% CI 2.57-5.70). No symptoms were reported in 24% of the seropositive participants. Among the 47% who returned for a follow-up serology test, the seroreversion rate was 39.5% and the seroconversion rate was 2.2%. The incidence of reinfection in the seropositive group was zero. CONCLUSION: Although there is a decline in the IgG antibody signal over time, 60.5% of the seropositive HCWs maintain their seroconversion status after a median time of 5.5 months.

Healthcare workers (HCWs) are at the front line of the ongoing coronavirus pandemic.

Comprehensively evaluating SARS-CoV-2 seroprevalence among HCWs in a large healthcare system could help identify the impact that epidemiological factors and presence of symptoms have on immune response to the infection over time.

To determine the seroprevalence of SARS-CoV-2 specific antibodies among healthcare workers (HCWs), to identify associated epidemiological factors and to study antibody kinetics.

We completed a longitudinal evaluation of the seroprevalence and epidemiology of SARS-CoV-2 specific antibodies in approximately 30,000 HCWs in the largest healthcare system in the State of Connecticut.

The baseline prevalence of SARS-CoV-2 antibody among 6,863 HCWs was 6.3% (95% CI: 5.7%-6.9%) and was highest among patient care support (16.7%), medical assistants (9.1%), and nurses (8.2%) and lower for physicians (3.8%) and advanced practice providers (4.5%).

Seroprevalence was significantly higher among African Americans (OR 3.26 compared to Caucasians, 95% CI 1.77-5.99), in participants with at least one COVID symptom (OR 3.00,

Healthcare workers (HCWs) are at the front line of the ongoing coronavirus pandemic [1] .

Assessing antibody response could provide a snapshot of the burden of infection among HCWs [2] . Studies of immune responses to SARS-CoV-2 showed presence of antibody titres 7-14 days following symptom onset [3] [4] [5] . These antibodies decline over time but may remain detectable for several months following infection [2, 6, 7] . SARS-CoV-2 antibodies have been shown to have neutralizing capacity in vitro and to confer protection against re-infection in challenge models [8] [9] [10] [11] .

Anti-SARS-CoV-2 seroprevalence among HCWs has ranged from 0% to 45.3% [12] . A comprehensive study of seroprevalence among HCWs in a large healthcare system could help identify the impact that epidemiological factors and presence of symptoms have on immune response to the infection over time. Our healthcare system is the largest in the State of Connecticut with over 30,000 employees, 7 acute care hospitals, the state's largest behavioral health network, rehabilitation services, a large physician group, skilled-nursing and home health services, and senior-living facilities. We determined the baseline prevalence of SARS-CoV-2 IgG antibodies and the epidemiological factors associated with it. This is one of the largest seroprevalence studies focusing on HCWs in a US healthcare system with longitudinal follow-up to investigate antibody kinetics.

Approximately 30,000 HCWs and affiliated medical staff were invited to participate via electronic communication. Due to the complexity of our healthcare system, recruitment and testing of subjects occurred in a staggered fashion; testing occurred from May 11 th to August J o u r n a l P r e -p r o o f 22 nd 2020 at eight testing sites ( 

Consented study participants were invited to schedule three appointments for blood draws at the initial visit, at approximately 2-4 weeks, and at 3-6 months after the initial visit. Results were made accessible to participants within 48 hours. Educational materials on how to interpret results, encouragement on continued use of PPE and caveats with regards to the uncertainty of the correlation between positive antibodies and protection against re-infection were also provided. All study activities were approved by our hospital's Institutional Review Board (HHC-2020-0103).

Samples were analyzed at our Ancillary Microbiology Laboratory using the Abbott Architect i2000 platform. Clinical assay performance was determined by the manufacturer but also validated by our ancillary laboratory in accordance with clinical laboratory regulations. The assay was performed in accordance with manufacturer instructions [13] . The assay is an automated, two-step chemiluminescent microparticle immunoassay for the qualitative detection of IgG antibodies to the nucleocapsid protein of SARS-CoV-2. Seropositivity was defined as IgG Index (Signal/Cutoff (S/C)) ≥1.4. The Index (S/C) provides a semi-quantitative concentration of IgG antibody to SARS-CoV-2. Per the manufacturer's package insert: the positive percent agreement was 100% (95% CI: 95.89, 100.00) in molecular positive patients (N=31) tested after 14 days from symptom onset and the negative percent agreement was 99.6% (95% CI: 99.05, 99.90).

Descriptive statistics comprise means and standard deviations (SD) for normally distributed continuous variables and medians and interquartile ranges for non-normally distributed J o u r n a l P r e -p r o o f continuous variables. Categorical variables are reported as frequencies, using percentages. Inferential statistics comprised a Student's t-test or Mann-Whitney U test, depending on distribution, for two-group comparisons of continuous variables. Categorical variables were evaluated with a chi square test. A forward stepwise logistic regression model was constructed to evaluate factors that might be significantly associated with baseline seropositivity among the entire sample. Factors that showed univariate differences at p≤0.10 were included in the model, which was iterated until no significant change in the model's overall Wald score was observed.

Odds ratios (OR) and 95% confidence intervals (CI) were calculated.

All statistics were analyzed with SPSS v. 26 (IBM; Armonk, NY 2019) using an a priori alpha level of 0.05 such that all results yielding p<0.05 were deemed statistically significant. No power analysis was conducted, as the study was open to all respondents meeting enrollment criteria.

A total of 8,663 HCWs provided electronic consent and 6863 (23% of our entire employee population) provided an initial sample. The average age of participants was 43.2 ± 12.9 years (median 43, range 18-81). Of the 6,811 participants who reported gender, there were 5387 females (79.1%).

Based on initial testing, 433 (6.3%; 95% CI: 5.7%-6.9%) participants were seropositive.

Demographic data and responses to COVID-19 exposure questions are presented in Table 2 .

African Americans had a greater rate of seropositivity than Caucasians (11.7% vs. 5.5%, p<0.001). Hispanics also had greater rate of seropositivity than non-Hispanics (10.2% vs. 5.9%, p<0.001).

Seropositivity varied significantly (p<0.001) according to healthcare role (Table 3 ; responses from 6774/6863). When roles comprising at least 2% of the 6774 respondents were evaluated, the greatest seropositivity was seen in patient care support (16.7%), medical assistants (9.1%), nurses (8.2%), physical/occupational therapists (7.4%) and administrative assistants (6.5%).

Seropositivity was 3.8% for physicians and 4.5% for advanced practice providers.

Of the seropositive participants, 328 (75.2%) reported symptoms suspicious for COVID-19 after 

Seropositivity rates differed significantly (p<0.001) based on self-reported exposure to SARS-CoV-2: 4.1%, 6.1%, and 7.9% in those with none, occasional, and daily exposure, respectively.

Rates of seropositivity were higher in HCWs who were placed on home quarantine based on symptoms or a positive PCR test (33.6% vs. 2.7%; p<0.0001) and those with exposure to COVID-19 outside of the hospital (15.9% vs. 5.6%; p<0.0001). In addition, 880 of 6821 (12.9%) of the HCWs reported at least one high-risk exposure (i.e., contact with a COVID-19 positive patient without proper PPE) and were more than twice as likely (p<0.001) to test seropositive (12.8%) as those without such an exposure (5.4%).

J o u r n a l P r e -p r o o f

One thousand three hundred and seventeen (1317) 

When the baseline variables were evaluated in a multivariate model, African American race (OR (Table 4 ).

J o u r n a l P r e -p r o o f Two thousand three hundred and seven (2307) of the 6863 (33.6%) original participants had a second serology test after a median time of 25 days (range: 10-40 days). Of these 2307 participants, 194 (8.4%) were seropositive on the first serology test. One hundred and eightyfive (95.3%) of those seropositive on the first serology test were seropositive on the second serology test (9 or 4.6% seroreverted). Eleven (0.5%) of those who were seronegative on the first serology test were seropositive on the second serology test. Eighty seven participants who had the second testing outside the 10-40 day time frame were excluded. Only one of the 87 subjects had change in the serology status (from initial positive to just below the threshold negative). 

The Centers for Disease Control and Prevention (CDC) conducted a nationwide commercial laboratory seroprevalence survey starting on April 26, 2020 [14] . We matched testing dates with the CDC study and compared seropositivity rates in Connecticut to the seropositivity rates found in our study (Figure 1 ). Although the initial testing in May showed a higher seroprevalence among HCWs compared to the public (6.8% vs. 5.2%), subsequent testing revealed comparable rates of seropositivity. In a study of seroprevalence in the general population in Connecticut, conducted between June 10 and July 29, 2020, 567 participants were tested for presence of IgG J o u r n a l P r e -p r o o f against SARS-CoV-2 resulting in a weighted seroprevalence of 4.0% (90% confidence interval 2.0-6.0) [15] . During the same testing dates, the seroprevalence among HCWs in our study was 6.2%.

We assessed the impact the coronavirus pandemic has had on our workforce and identified epidemiological factors associated with its distribution. The seroprevalence rate of the initial phase of our study was 6.3% and the subsequent seroconversion rate was 0.5% at the second testing and 2.2% at the third testing phase. Throughout the duration of the study the seropositivity rate was 7.4% (508 of 6,863). Published studies of seroprevalence among HCWs in the US report rates between 6% and 35.8% [16] [17] [18] [19] [20] [21] [22] .

A recent meta-analysis of seroprevalence of SARS-CoV-2 antibodies in HCWs by Galanis et al.

included 127,480 HCWs from 49 studies [12] . The estimated overall seroprevalence rate was 8.7% (95% CI: 6.7-10.9%). Seroprevalence was higher in studies that were conducted in North America (12.7%). Factors associated with seropositivity included male gender, Black, Asian, and Hispanic race/ethnicity, working in a COVID-19 unit, working in areas with PPE shortage, selfreported belief of previous SARS-CoV-2 infection, previous PCR test, and household contact with suspected or confirmed COVID-19 patients. The higher rate of seropositivity that we observed in females may be due to the fact that 35.8% of enrolled HCWs in our study were nurses and 91% of nurses were females. The racial and ethnic disparity that we observed in the rates of seropositivity among our HCWs mirrors the findings of prior studies [18, 22, 23] . In Connecticut, the weighted seroprevalence among Blacks was 6.4% and among Hispanics 19.9% compared to the overall weighted seroprevalence of 4.0% [15] . This difference may be partially J o u r n a l P r e -p r o o f explained by existing disparities in access to healthcare, financial inequality, and high-density urban living. Our healthcare system has applied strategies to mitigate the effect that these socioeconomic disparities may have on the welfare of our minority employees.

Prior studies have shown inconsistent results about the effect of age on seroprevalence [24, 25, 26] . This is not surprising considering the geographic variations of the exposure of the population to SARS-CoV-2. In our study the age group 50-59 years was associated with a higher seroprevalence rate.

In a large observational cohort study of 28,792 HCWs in Denmark, seroprevalence was higher in HCWs (4.04%) than in blood donors (3.04%) [24] . Seroprevalence was higher in male HCWs (risk ratio 1.49), frontline HCWs (risk ratio 1.38) and those working on dedicated COVID-19 wards (risk ratio 1.65). As in our study, a stepwise increase in seropositivity was observed with increase in job-related exposure.

A Swedish study reported an overall seropositivity rate of 19.1%, with nurses having a higher rate (35%) than physicians (21%) and assisting nurses (27%), in a sample of 2,149 HCWs [27] .

In a study of 40,329 HCWs in the Greater NYC Area, the overall seroprevalence rate was 13.7%, with service/maintenance HCWs having the highest rate (20.9%) followed by nurses (13.1%), administrative and clerical (12.6%), allied health professionals (11.6%) and physicians (8.7%) [21] . In a study by Shields et al., seroprevalence was highest in HCWs working in housekeeping (34.5%), acute medicine (33.3%) and general internal medicine (30.3%) and lowest in those working in intensive care (14.8%), emergency medicine (13.3%,) and general surgery (13.0%) [28] . In our study, the seropositivity rate of nurses was twice as high as that of physicians and the healthcare roles with the highest seroprevalence rate was patient care support (16.7%).

In a study by Moncunill et al., 578 HCWs had serial levels of IgM, IgA, and IgG over the course of 3 months [29] . The initial combined seropositivity rate was 9.3% and increased to 14.5% at 1 month. The seroreversion rate at 3 months was 77.6% for IgM, 3.7% for IgG, and 24.5% for IgA.

Self et al. looked at 3,248 frontline HCWs at 13 centers in 12 states who were tested for SARS-CoV-2 immunoglobulins (IgA, IgM, or IgG) at baseline and 60 days later [30] . The initial seroprevalence was 6.0% and at 60 days the seroreversion rate was 28.2%. In our study, the seroreversion rate at 5.5 months (median time) was 39.5%. The authors concluded that a substantial number of HCWs infected with SARS-CoV-2 might have negative serologic test results in the months following infection. This is an important consideration when serology is used as a marker of prior SARS-CoV-2 infection and although humoral immunity may decline with time, protection against future SARS-CoV-2 infections may be rendered by memory B-cells and T-cells.

Interestingly, we found that only 75% of the seropositive HCWs had a prior positive PCR test and 24% reported no prior COVID-19 symptoms which may suggest a significant rate of asymptomatic infection among HCWs. Our results correspond with other reports of asymptomatic or mild infection among the general population in Iceland, among homeless shelter residents in Boston and among PCR positive HCWs in the Netherlands [7, 31, 32] . In a meta-analysis of asymptomatic patients as a source of COVID-19 infections, the rate of asymptomatic cases was 24.2% [33] . In a study of HCWs in a pediatric dialysis unit, 11 of 25 (44%) HCWs seroconverted and 24/25 (96%) were asymptomatic [34] .

Such a high rate of asymptomatic infections may pose a risk of transmission to other staff members and to the patients they serve. In the early phases of the pandemic, when PCR testing was not widely available, patients reporting symptoms suspicious for COVID-19 infection were J o u r n a l P r e -p r o o f asked to quarantine. As guidance evolved, our healthcare system mandated universal masking for HCWs on March 27, 2020 and for patients and visitors on April 24, 2020. Universal screening for symptoms was implemented in March 2020. Targeted PCR testing for SARS-CoV-2 became available to HCWs with suspicious symptoms or exposure without proper PPE in April 2020.

Voluntary PCR testing for SARS-CoV-2 became available on June 11, 2020.

Presence of IgG antibodies against SARS-CoV-2 may have conferred immunity to our HCWs considering the difference in the incidence of a positive PCR test between the seropositive group (0%; testing at least 30 days after the original serology test) and the seronegative group (1.3%; after a median follow-up of 72.4 days). Lumley et al.[35] noted that the incidence of a positive PCR test was 1.09 per 10,000 days at risk in the seronegative group versus 0.13 per 10,000 days at risk in the seropositive group. The authors concluded that the presence of IgG antibodies against SARS-CoV-2 was associated with a substantially reduced risk of reinfection in the ensuing 6 months.

Recruitment was limited to employees who had access to communication via electronic devices.

Only 23% of our 30,000 HCWs participated, and of those, 47% had a third test. Some HCWs may have limited understanding of English or may be wary of participation in an employersponsored research study. Enrollment was not random, thus motivation to participate may have been influenced by health-seeking behavior and curiosity about serology status, especially among those with prior positive PCR test or close contact with SARS-CoV-2. Thus, these findings may not truly reflect the entire population of our HCWs. Executing this study across a complex healthcare system of 7 acute care hospitals, in the middle of the pandemic and with J o u r n a l P r e -p r o o f competing resources for testing was extremely challenging. The testing intervals were not as narrow as we would like them to be and not all participants were offered subsequent testing at the same time frames.

The seroprevalence rate of SARS-CoV-2 specific antibodies among our HCW was comparable to the rate found in the general population of Connecticut. Seropositivity was associated with African American race, presence of at least one COVID symptom, prior positive PCR and prior quarantine. Twenty-five percent of the HCWs reported no prior symptoms suspicious for viral infection. At a median time of 5.5 months, the seroreversion rate was 39.5% and the seroconversion rate was 2.2%. The incidence of reinfection was 0% in the seropositive group and the incidence of a positive PCR test was 1.2% in the seronegative group. Further studies are needed to determine the impact that PPE availability, severity of symptoms and degree of ongoing exposure have on rates of seroconversion and the duration of seropositivity among HCWs. J o u r n a l P r e -p r o o f 

Epidemiology of and Risk Factors for Coronavirus Infection in Health Care Workers: A Living Rapid Review

Antibody responses to SARS-CoV-2 in patients with COVID-19

Kinetics of viral load and antibody response in relation to COVID-19 severity

Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals

Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients

Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19

Humoral Immune Response to SARS-CoV-2 in Iceland

Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques

Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months

Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers, and convalescent plasma donors

Seroprevalence of SARS-CoV-2 antibodies and associated factors in health care workers: a systematic review and meta-analysis

Manufacturer package insert information: Abbott Laboratories, Diagnostics Division

Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study

Prevalence of SARS-CoV-2 Infection Among Health Care Workers in a Tertiary Community Hospital

The prevalence of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) IgG antibodies in intensive care unit (ICU) healthcare personnel (HCP) and its implications-a single-center, prospective, pilot study

Seroprevalence of SARS-CoV-2 Among Frontline Health Care Personnel in a Multistate Hospital Network -13 Academic Medical Centers

Seroprevalence of SARS-CoV-2 Among Frontline Healthcare Personnel During the First Month of Caring for COVID-19 Patients

Antibodies Among Healthcare Workers at a Tertiary Academic Hospital in New York City

Antibodies in Health Care Personnel in the New York City Area

Antibody evidence of SARS-CoV-2 infection in healthcare workers in the Bronx

Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York

Risk of COVID-19 in health-care workers in Denmark: an observational cohort study

Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China

SARS-CoV-2 serosurvey in health care workers of the Veneto Region

SARS-CoV-2 exposure, symptoms and seroprevalence in healthcare workers in Sweden

SARS-CoV-2 seroprevalence and asymptomatic viral carriage in healthcare workers: a cross-sectional study

SARS-CoV-2 seroprevalence and antibody kinetics among health care workers in a Spanish hospital after three months of follow-up

Decline in SARS-CoV-2 antibodies after mild infection among frontline health care personnel in a multistate hospital network -12 States

Prevalence of SARS-CoV-2 Infection in Residents of a Large Homeless Shelter in Boston

Prevalence and Clinical Presentation of Health Care Workers With Symptoms of Coronavirus Disease 2019 in 2 Dutch Hospitals During an Early Phase of the Pandemic

Asymptomatic patients as a source of COVID-19 infections: A systematic review and meta-analysis

Asymptomatic Seroconversion of Immunoglobulins to SARS-CoV-2 in a Pediatric Dialysis Unit

Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers

We thank Jamie Fish-Furhman and the project management team for their assistance with study implementation. Our deep appreciation is extended to all staff for their courage and dedication to patient care.J o u r n a l P r e -p r o o f